Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.

Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.

DNA vectors have been widely used as a priming of poxvirus vaccine in prime/boost regimens. Whether the number of DNA impacts qualitatively or quantitatively the immune response is not fully explored. With the aim to reinforce T-cell responses by optimizing the prime-boost regimen, the multicentric...

Full description

Bibliographic Details
Main Authors: Yves Lévy, Christine Lacabaratz, Kim Ellefsen-Lavoie, Wolfgang Stöhr, Jean-Daniel Lelièvre, Pierre-Alexandre Bart, Odile Launay, Jonathan Weber, Bernd Salzberger, Aurélie Wiedemann, Mathieu Surenaud, David M Koelle, Hans Wolf, Ralf Wagner, Véronique Rieux, David C Montefiori, Nicole L Yates, Georgia D Tomaras, Raphael Gottardo, Bryan Mayer, Song Ding, Rodolphe Thiébaut, Sheena McCormack, Geneviève Chêne, Giuseppe Pantaleo
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-06-01
Series:PLoS Pathogens
Online Access:https://doi.org/10.1371/journal.ppat.1008522

Internet

https://doi.org/10.1371/journal.ppat.1008522

Similar Items